查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1848799

放射腫瘤市場按組件、放射治療類型、技術、應用和最終用戶分類－2025-2032年全球預測

Radiotherapy Market by Component, Radiotherapy Type, Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，放射治療市場規模將達到 130.9 億美元，年複合成長率為 6.77%。

關鍵市場統計數據
基準年 2024 77.5億美元
預計年份：2025年 82.5億美元
預測年份 2032 130.9億美元
複合年成長率 (%) 6.77%

當今放射腫瘤學的策略概述：重點關注技術發展、臨床重點以及影響投資獲取和患者照護服務的市場力量。

放射治療是多學科癌症診療的基石，它結合了精準技術、臨床經驗和不斷發展的治療模式，旨在改善多種惡性腫瘤的治療效果。過去十年，臨床實踐已從統一的放射治療模式轉向高度個人化的治療方案，整合了先進的影像技術、自適應計劃和多模式治療。這項轉變提升了供應商、服務供應商和醫療系統的作用，他們不僅需要提供設備，還需要提供整合的工作流程，將技術能力轉化為可衡量的臨床效益。

因此，醫療決策者面臨一系列複雜的權衡取捨：資本密集度與生命週期成本、臨床療效與工作流程效率、員工能力和培訓需求，以及與報銷和法律規範的契合度。這些因素的交互作用影響籌資策略、供應商合作關係和臨床實施時間表。此外，軟體、影像引導和粒子療法等領域的技術創新正在重新定義營運可行性和臨床需求，迫使領導者定期重新評估投資重點。

本導言為後續內容奠定了基礎，提供了一份實用且基於實證的執行摘要，獎勵綜合分析了技術變革、監管壓力、供應鏈動態以及相關人員。本書旨在幫助企業主管清楚了解放射治療的發展方向，以及如何將新技術轉化為永續的臨床和財務成果。

本書對正在重塑放射治療服務模式、報銷動態和相關人員期望的重大技術、臨床和營運變革進行了深入分析。

放射治療領域正經歷著一場變革性的轉變，影像、計算和粒子束傳輸技術的融合正在重新定義臨床應用的可能性和運作模式。影像導引和自適應計劃的治療進展正將重點從靜態治療方案轉向動態的、基於解剖生物學的策略，從而能夠在縮小照射範圍和提高劑量的同時，更好地保護正常組織。粒子治療，特別是質子和碳離子治療的同步發展，正在拓展針對解剖結構複雜和放射抗性腫瘤的治療手段，迫使醫療系統在臨床差異化治療和資金投入之間尋求平衡。

在技​​術方面，即時顯像模式（包括磁振導航系統）的整合，以及自動化治療計劃和劑量計算軟體的日益成熟，正在重塑臨床醫生的工作流程，並縮短治療計劃的周轉時間。人工智慧和機器學習正在推動勾畫輪廓、計劃最佳化和品質保證的進步，提高一致性，同時也對檢驗、可解釋性和法律規範方面提出了新的考慮。這些功能正日益融入供應商生態系統，使軟體從輔助角色轉變為價值提案的核心。

同時，從維護和校準到專業培訓和諮詢，服務和售後支援正成為長期臨床成功的關鍵決定因素。對技術精湛的放射腫瘤團隊的需求，以及最佳化診療流程和展現價值導向型療效的壓力，正在推動對遠距服務平台、廠商主導的教育和臨床夥伴關係的投資。這些轉變表明，市場重視的是整合解決方案、經證實有效的臨床效用以及能夠適應快速技術創新的穩健營運模式。

深入評估2025年美國關稅如何改變放射腫瘤學生態系統中的採購、製造和服務格局，並重塑供應商策略。

2025年對部分進口放射治療設備及組件徵收關稅的措施，對採購、製造和臨床營運產生了即時的連鎖反應。由於供應商調整定價策略、改變供應鏈並重新佈局區域生產，資本設備採購者如今面臨更高的購買成本和更長的採購週期。醫院財務團隊必須制定能夠預見更高總擁有成本（TCO）的資本計劃，而採購部門則在重新談判合約並尋找替代供應商，以減輕短期預算壓力。

關稅主導的成本壓力也在改變供應商的行為。為了保持企業發展競爭力，全球多元化製造商正在加速關鍵零件的在地化，並將組裝業務轉移到免稅地區。規模較小、生產彈性較低的供應商面臨不成比例的利潤壓縮，迫使它們減少創新投資或透過與大型企業建立策略聯盟進行整合。同時，由於進口備件和特殊零件面臨海關延誤和更高的到岸成本，服務網路和售後支援也受到影響，這給運作承諾和維護服務等級協定 (SLA) 帶來了挑戰。

在臨床營運方面，關稅促使人們更加關注資產利用率、維修和服務主導收入模式。醫療系統正在評估租賃協議、供應商融資和維護合約延期等方案，以緩解不斷上漲的資本支出。同時，支付方和政策制定者正在仔細審查成本走勢和治療價值，並向供應商施壓，要求其證明更高的前期成本具有合理的臨床和經濟效益。最終，關稅將推動供應鏈韌性策略的製定，盡可能促進在地化生產，並加速創新合約的製定，以平衡財務限制與維持高品質癌症治療的需求。

綜合細分分析將組成臨床模式技術、解剖學應用和最終用戶畫像與策略性產品定位和服務產品連結起來。

細緻的細分框架涵蓋組件、放射治療類型、技術層級、應用和最終用戶，明確了臨床需求與商業機會和營運複雜性之間的交集。從組件角度來看，硬體仍然是重點，包括近距離放射後荷機裝機、伽瑪刀系統、影像引導系統、線性加速器（linac）、多葉准直器（MLC）和質子治療系統等複雜設備。服務透過維護和校準、專業培訓和諮詢來補充硬體，從而確保臨床設備的執行時間和員工的專業能力。劑量計算引擎、病患工作流程系統和治療計畫套件等軟體層透過實現治療路徑中的可重複性、自動化和互聯互通，日益提升了價值提案。

在考慮放射治療類型時，區分近距離放射治療、體外放射治療和全身放射治療有助於明確臨床應用情境和採購理由。體外放射治療本身涵蓋多種模式，例如3D適形影像導航放射治療放射治療、強度調控放射治療、質子治療、立體定位放射治療、立體定位放射手術、螺旋斷層放射線手術治療和容積旋轉調強放射治療，每種模式都有其自身的基礎設施、人員配備和品質保證要求。全身放射治療治療方法，例如放射免疫療法、放射性藥物療法和標靶α療法，將放射治療原理擴展到系統腫瘤學實踐中，需要與製藥、核子醫學和監管機構等相關人員合作。

透過對先進放射治療和傳統放射治療進行技術細分，可以揭示其應用路徑。以影像導航放射治療和粒子治療為特徵的先進放射治療需要更高的資本投入、專門的工作流程和完善的臨床醫生培訓，但能夠提供具有臨床意義的劑量適形性。粒子治療的亞型，例如碳離子、中子和質子，具有獨特的生物學和治療特性，這些特性會影響轉診模式和設施設計。基於腫瘤部位（腦、乳房、子宮頸、結直腸、胃腸道、頭頸部、肝臟、肺部、前列腺和脊椎）的應用細分，可反映臨床優先事項和技術適用性。對先進放射腫瘤中心、醫院和腫瘤診所等最終用戶進行細分，可以揭示其採購能力、人員配備模式和患者數量的差異。將這些相互交織的層面結合起來，透過將技術能力與實際臨床和營運限制相結合，可以指導產品開發、服務設計和市場推廣策略。

提供有關亞太地區應用促進因素、監管環境、供應鏈差異和臨床基礎設施趨勢的實用區域資訊。

區域動態對技術採納、監管預期和投資策略有顯著影響，美洲、歐洲、中東和非洲以及亞太地區呈現出截然不同的特徵。在美洲，先進的癌症中心和私人醫院系統通常優先考慮快速部署影像引導系統和擴充性的服務協議，但它們在複雜的報銷框架下營運，這些框架影響資本核准流程和患者就醫途徑。供應鏈因素和關稅的影響會影響依賴進口的零件，進而引發區域製造的討論，進而影響採購時間表和定價基準。

在歐洲、中東和非洲，資金雄厚的醫療體係正積極推動精準放射治療和粒子治療，而其他市場則著重於提升基礎放射治療能力，以滿足尚未滿足的臨床需求。各地區的法規環境差異顯著，影響醫療器材的核准途徑、臨床試驗的進行以及跨國合作。培訓和人才發展仍然是多個市場面臨的持續限制因素，凸顯了可擴展的遠端教育和廠商主導的能力建構專案的重要性。

亞太地區基礎設施投資迅速成長，公立和私立腫瘤服務也呈現強勁成長動能。大型轉診中心主導質子治療、磁振導航系統和整合軟體平台的普及，而新興市場則優先考慮經濟高效的直線加速器部署和服務可靠性。本地製造能力、政府主導的醫療保健計劃以及官民合作關係共同塑造了該地區的發展軌跡，而那些構建靈活資金籌措模式和穩定服務網路的供應商往往能夠獲得更深層次的市場滲透。在所有地區，互通性標準、資料管治和價值驗證都是影響長期應用和跨國合作的通用主題。

這份富有洞察力的競爭分析報告詳細闡述了製造商、軟體創新者和服務提供者如何透過合作售後服務和靈活的商業模式實現差異化競爭優勢。

放射治療生態系統中的主要企業正在推行差異化策略，將技術創新、卓越服務和策略夥伴關係結合。現有設備製造商持續投資於整合系統，這些系統融合了硬體、先進的影像處理和軟體主導的規劃，旨在透過服務和軟體授權建立更牢固的客戶關係並創造持續的收入來源。這些現有企業也在拓展售後服務，例如預測性維護和遠距離診斷，以提高運作並保護其長期安裝設備的價值。

同時，軟體供應商和數位醫療參與企業的新興企業正透過提供自動化、工作流程編配和結果分析等服務來擴大自身影響力，以彌補臨床醫生效率和品質保證方面的不足。專注於人工智慧驅動的輪廓勾畫、自適應規劃和劑量最佳化的新創公司正與醫療器材製造商和學術中心建立策略聯盟，以檢驗其臨床效用並加速獲得監管部門的認可。與學術界和臨床界領導夥伴關係是獲得真實世界證據和與支付方建立聯繫的關鍵橋樑。

競爭格局也體現在零件供應商和服務供應商的整合上，因為各公司都在尋求規模優勢，以支援全球服務網路和在地化生產。那些將深厚的臨床經驗與靈活的商業模式（例如租賃、按使用付費和與療效掛鉤的合約）相結合的公司，更有能力應對採購限制並展現投資回報。整體而言，競爭格局有利於那些能夠提供可驗證的臨床價值、強大的支援體係以及靈活的資金籌措，以滿足全球醫療保健系統多樣化需求的公司。

為加強供應鏈韌性、加速臨床應用、增強員工隊伍以及使商業模式與價值主張保持一致，提出切實可行的管理建議和優先事項。

產業領導者應採取組合策略，兼顧短期抗風險能力及長期臨床差異化優勢。盡可能實現供應鏈多元化和零件本地化，可以降低關稅波動和海關延誤帶來的風險。採購團隊應評估收購、租賃和績效合約等多種方案，以最佳化資本利用率，並協調供應商和醫療系統之間的獎勵。

投資於數位化準備和員工能力將帶來豐厚回報。供應商和醫療機構應共同投資於培訓專案、遠端服務能力以及決策支援工具的整合，以減少差異並加速先進工作流程的採用。透過產生嚴謹的真實世界證據來證明臨床和經濟價值，對於獲得報銷和證明昂貴技術的合理性至關重要。同時，企業必須制定清晰的監管策略，以應對人工智慧、醫療器材軟體和粒子療法等領域不斷變化的標準。

與學術中心、支付方和多學科腫瘤網路建立夥伴關係，有助於促進臨床檢驗並擴大轉診管道。領導者還應尋求模組化產品架構和可互通的軟體平台，以實現漸進式升級並順利整合到現有臨床生態系統中。結合供應鏈韌性、教育投入、實證實踐和靈活的商業模式，可以幫助機構抵禦短期不利因素，同時為永續成長和臨床影響力奠定基礎。

對混合方法研究框架（包括專家訪談、文獻綜述、監管分析和供應鏈分析）進行清晰的解釋，以支持相關見解和建議。

本執行摘要的分析是基於嚴謹的混合方法研究設計，該設計綜合運用了訪談、臨床文獻、監管記錄和供應鏈資訊。主要研究包括與放射腫瘤學家、醫學物理學家、醫院採購負責人以及供應商和服務供應商的高級管理人員進行結構化討論，以獲取關於技術效用、推廣障礙和營運限制的第一手觀點。臨床實務趨勢的分析則透過對同儕審查出版物、臨床指南和會議論文集的系統性回顧來佐證，以確保其與最新證據和新興共識保持一致。

二級資訊來源包括監管文件、設備技術文件和公開的服務協議，用於梳理產品功能、認證途徑和合約規範。供應鏈分析利用進出口資料、零件採購趨勢和生產佈局圖來評估弱點和潛在的緩解策略。品質保證通訊協定包括訪談結果的交叉檢驗、專家反覆評審和情境測試，以探討關稅、技術採納曲線和勞動趨勢的影響。在適用情況下，也考慮了倫理考量和資料管治問題，以確保所提出的建議符合病患安全和隱私標準。

此調查方法強調透明度、可重複性和與管理決策的相關性，既反映了臨床實踐的現實，也反映了相關人員可用的策略槓桿。

簡潔扼要的結論強調了建立具有韌性的策略創新夥伴關係關係和產生證據對於提供永續的、高品質的放射治療服務的重要性。

放射腫瘤學領域正處於曲折點，技術進步、商業策略和醫療系統優先事項正在交匯融合，共同塑造癌症治療的新時代。精準成像、自適應計畫和粒子療法在拓展臨床選擇的同時，也提高了對訓練、服務可靠性和資金籌措的要求。受關稅主導的供應鏈變化和採購模式的轉變，凸顯了製定靈活且具有韌性的策略的必要性，這些策略既要確保臨床服務的可及性，又要控制對總成本的影響。

高階主管應著重整合先進技術，以帶來可衡量的臨床效益；投資於員工能力建構；並建構確保執行時間和長期價值的服務模式。供應商、臨床領導者和支付者之間的協作對於展現成果和協調獎勵至關重要。最終，在快速變化的環境中，具備營運韌性、實證實踐能力和以患者為中心的醫療機構將成為提供高品質、永續放射治療服務的領導者。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 推出一款利用人工智慧技術最佳化治療效率和準確性的自動化治療計畫系統
  • 整合式磁振造影導引放射治療系統可以實現即時軟組織視覺化和自適應劑量控制。
  • 質子治療中心擴建工程為兒童和複雜腫瘤患者提供更多精準治療選擇
  • 低分割放射治療通訊協定正被擴大用於減少患者就診次數和提高生活品質。
  • 超高劑量率加速FLASH放射療法的出現增強了正常組織的保護作用
  • 利用放射組學和基因組學數據進行個人化自適應治療計劃
  • 推出雲端基礎的腫瘤學平台，以促進放射治療領域的遠距協作和巨量資料分析

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按組件分類的放射治療市場

  • 硬體
    • 近距離放射治療後荷機
    • 伽瑪刀系統
    • 成像和導引系統
    • 線性加速器（LINAC）
    • 多葉準直器（MLC）
    • 質子治療系統
  • 服務
    • 維護和校準
    • 培訓和諮詢
  • 軟體
    • 劑量計算
    • 病患工作流程系統
    • 治療計劃

第9章 放射治療市場：放射治療類型

  • 近距離放射治療
  • 體外放射治療
    • 3D適形放射治療
    • 影像導航放射治療
    • 強度調控放射治療
    • 磁振導航放射治療
    • 質子治療
    • 立體定位放射治療
    • 立體定位放射放射線手術
    • 斷層掃描
    • 容積調強弧形治療
  • 系統性放射治療
    • 放射免疫療法
    • 基於放射性藥物
    • 標靶α療法

第10章 放射治療市場：依技術分類

  • 先進的放射治療
    • 影像導航放射治療
    • 粒子束療法
      • 碳離子
      • 中子
      • 質子
  • 常規放射治療

第11章 放射治療市場：依應用領域分類

  • 腦腫瘤
  • 乳癌
  • 子宮頸癌
  • 大腸直腸癌
  • 消化系統癌症
  • 頭頸癌
  • 肝癌
  • 肺癌
  • 攝護腺癌
  • 脊椎癌

第12章 放射腫瘤市場（依最終用戶分類）

  • 高級放射腫瘤中心
  • 醫院
  • 腫瘤診所

第13章 放射腫瘤市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 放射腫瘤市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國放射腫瘤市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Accuray Incorporated
    • Agilent Technologies Inc.
    • Cardinal Health, Inc.
    • Charles River Laboratories International, Inc.
    • Elekta AB
    • GE HealthCare Technologies Inc.
    • IBA Dosimetry GmbH
    • IntraOp Medical, Inc.
    • Koninklijke Philips NV
    • Leo Cancer Care
    • Mevion Medical Systems, Inc.
    • Panacea Medical Technologies Pvt. Ltd.
    • Revvity, Inc.
    • Epsilon Elektronik by BOZLU HOLDING Corporation
    • Siemens AG
    • ZEISS Group
    • Canon Medical Systems Corporation
    • Hitachi, Ltd.
    • ViewRay Technologies, Inc.
    • BEBIG Medical GmbH
    • Vision RT Ltd.
    • Toshiba Corporation
    • Mitsubishi Electric Corporation
    • RefleXion Medical Inc.
    • Sumitomo Heavy Industries Ltd.
Product Code: MRR-42653751E6AE

The Radiotherapy Market is projected to grow by USD 13.09 billion at a CAGR of 6.77% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.75 billion
Estimated Year [2025] USD 8.25 billion
Forecast Year [2032] USD 13.09 billion
CAGR (%) 6.77%

Strategic overview of radiotherapy today highlighting technological evolution clinical priorities and market forces that influence investment procurement and patient care delivery

Radiotherapy remains a cornerstone of multidisciplinary cancer care, combining precision technology, clinical expertise, and evolving treatment paradigms to improve outcomes across a broad spectrum of malignancies. Over the last decade, clinical practice has shifted from one-size-fits-all radiation delivery toward highly individualized approaches that integrate advanced imaging, adaptive planning, and combined modality treatments. This evolution has elevated the role of vendors, service providers, and health systems in delivering not only equipment but also integrated workflows that translate technological promise into measurable clinical benefits.

Consequently, institutional decision-makers face a complex matrix of trade-offs: capital intensity and lifecycle costs, clinical performance and workflow efficiency, workforce competencies and training needs, and alignment with reimbursement and regulatory frameworks. The interplay of these factors shapes procurement strategies, vendor partnerships, and clinical adoption timelines. Moreover, innovation in software, image guidance, and particle therapies is redefining what is operationally feasible and clinically desirable, prompting leaders to reassess investment priorities regularly.

This introduction sets the stage for a pragmatic, evidence-driven executive summary that synthesizes technological shifts, regulatory pressures, supply chain dynamics, and stakeholder incentives. It aims to equip executives with a clear-eyed understanding of where radiotherapy is heading and how to translate emerging capabilities into sustainable clinical and financial outcomes.

Compelling analysis of the major technological clinical and operational shifts redefining radiotherapy delivery models reimbursement dynamics and stakeholder expectations

The radiotherapy landscape is undergoing transformative shifts driven by convergence of imaging, computation, and particle delivery innovations that are redefining clinical possibilities and operational models. Advances in image-guidance and adaptive planning have shifted emphasis from static treatment prescriptions toward dynamic, anatomy- and biology-driven strategies, enabling tighter margins and dose escalation with improved normal tissue sparing. Parallel progress in particle therapy, particularly proton and carbon-ion modalities, has expanded the therapeutic arsenal for anatomically complex and radioresistant tumors, prompting health systems to weigh capital intensity against clinical differentiation.

On the technology front, the integration of real-time imaging modalities, including MR-guided systems, and the maturation of automated treatment planning and dose calculation software are reshaping clinician workflows and reducing planning turnaround times. Artificial intelligence and machine learning are advancing contouring, plan optimization, and quality assurance, improving consistency while creating new considerations around validation, interpretability, and regulatory oversight. These capabilities are increasingly embedded into vendor ecosystems, moving software from a supportive role toward a central position in value propositions.

Simultaneously, services and aftermarket support-ranging from maintenance and calibration to specialized training and consulting-are becoming critical determinants of long-term clinical success. The need for skilled radiation oncology teams, combined with pressures to optimize throughput and demonstrate value-based outcomes, is fueling investments in remote service platforms, vendor-led education, and clinical partnerships. Together, these shifts indicate a market that prizes integrated solutions, demonstrated clinical utility, and resilient operational models capable of adapting to rapid technological change.

In-depth evaluation of how the 2025 United States tariff measures altered procurement manufacturing and service dynamics and reshaped vendor strategies across radiotherapy ecosystems

The introduction of tariffs on select imported radiotherapy equipment and components in 2025 has introduced immediate and cascading effects across procurement, manufacturing, and clinical operations. Capital equipment buyers now face elevated acquisition costs and longer procurement cycles as vendors adjust pricing strategies, re-route supply chains, and recalibrate regional manufacturing footprints. Hospital finance teams must reconcile capital planning with potential increases in total cost of ownership, while procurement offices seek contract renegotiations and alternative supplier arrangements to mitigate near-term budgetary impacts.

Tariff-driven cost pressures have also altered vendor behavior. Manufacturers with diversified global footprints have accelerated localization of critical components or shifted assembly operations to tariff-exempt jurisdictions to preserve competitive pricing. Smaller suppliers with limited manufacturing flexibility face disproportionate margin compression, which can reduce innovation investment or prompt consolidation through strategic partnerships with larger players. At the same time, service networks and aftermarket support are affected as imported spare parts and specialized components encounter customs delays and higher landed costs, challenging uptime commitments and maintenance SLAs.

For clinical operations, the tariffs have sharpened attention on asset utilization, refurbishment, and service-driven revenue models. Health systems are increasingly evaluating leasing arrangements, vendor financing, and extended maintenance contracts to smooth capital expenditure spikes. In parallel, payers and policy makers are scrutinizing cost trajectories and therapeutic value, creating pressure on vendors to demonstrate clinical and economic benefits that justify higher upfront costs. Ultimately, the tariffs catalyze supply chain resilience strategies, push toward localized manufacturing where feasible, and accelerate creative contracting that balances fiscal constraints with the imperative to maintain high-quality cancer care.

Comprehensive segmentation analysis linking components clinical modalities technologies anatomical applications and end user archetypes to strategic product positioning and service offerings

A nuanced segmentation framework provides clarity on where clinical needs intersect with commercial opportunity and operational complexity, spanning components, radiotherapy types, technology tiers, applications, and end users. From a component perspective, hardware remains a focal point encompassing complex devices such as brachytherapy afterloaders, Gamma Knife systems, imaging and guidance systems, linear accelerators (LINACs), multileaf collimators (MLCs), and proton therapy systems. Service offerings complement hardware through maintenance and calibration as well as specialized training and consulting that sustain clinical uptime and workforce competency. Software layers, including dose calculation engines, patient workflow systems, and treatment planning suites, increasingly mediate the value proposition by enabling reproducibility, automation, and connectivity across the care pathway.

When examining radiotherapy types, distinctions among brachytherapy, external beam radiotherapy, and systemic radiotherapy clarify clinical use cases and procurement rationales. External beam radiotherapy itself spans modalities such as 3D conformal radiation therapy, image-guided radiation therapy, intensity-modulated radiation therapy, MR-guided radiotherapy, proton beam therapy, stereotactic body radiotherapy, stereotactic radiosurgery, TomoTherapy, and volumetric modulated arc therapy, each with unique infrastructure, staffing, and quality assurance implications. Systemic radiotherapy modalities, including radioimmunotherapy, radiopharmaceutical-based approaches, and targeted alpha therapy, extend radiotherapeutic principles into systemic oncology practice and require coordination with pharmacy, nuclear medicine, and regulatory stakeholders.

Technology segmentation between advanced radiotherapy and conventional radiotherapy highlights adoption pathways. Advanced radiotherapy, characterized by image-guided radiotherapy and particle therapy, demands higher capital intensity, specialized workflows, and robust clinician training but offers clinically meaningful dose conformality. Within particle therapy, subtypes such as carbon-ion, neutron, and proton modalities carry distinct biological and delivery characteristics that influence referral patterns and center design. Application-based segmentation across tumor sites-brain, breast, cervical, colorectal, gastrointestinal, head and neck, liver, lung, prostate, and spine-captures clinical priorities and technology suitability, while end-user segmentation across advanced radio oncology centers, hospitals, and oncology clinics reveals divergent procurement capabilities, staffing models, and patient volumes. Together, these intersecting layers of segmentation guide product development, service design, and market engagement strategies by aligning technical capabilities with real-world clinical and operational constraints.

Actionable regional intelligence describing adoption drivers regulatory realities supply chain distinctions and clinical infrastructure trends across the Americas EMEA and Asia Pacific

Regional dynamics exert a profound influence on technology adoption, regulatory expectations, and investment strategies, with distinct profiles across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, advanced cancer centers and private hospital systems often prioritize rapid adoption of image-guided systems and scalable service contracts, but they also operate under complex reimbursement frameworks that shape capital approval processes and patient access. Supply chain considerations and tariff impacts affect import-dependent components, prompting regional manufacturing conversations that influence procurement timetables and pricing benchmarks.

Europe, Middle East & Africa presents a heterogeneous landscape where well-resourced health systems pursue precision radiotherapy and particle therapy while other markets focus on expanding basic radiotherapy capacity to address unmet clinical need. Regulatory environments across the region vary significantly, influencing device approval pathways, clinical trial implementation, and cross-border collaboration. Training and workforce development remain persistent constraints in several markets, underscoring the importance of scalable remote education and vendor-led competency programs.

The Asia-Pacific region combines rapid infrastructure investment with strong growth in both public and private oncology services. Large referral centers lead adoption of proton therapy, MR-guided systems, and integrated software platforms, while emerging markets prioritize cost-effective linear accelerator deployments and service reliability. Regional manufacturing capabilities, government-sponsored health initiatives, and public-private partnerships shape expansion trajectories, and vendors that build flexible financing models and durable service networks tend to achieve deeper penetration. Across all regions, interoperability standards, data governance, and value demonstration are common themes that influence long-term adoption and cross-border collaboration.

Insightful competitive assessment outlining how manufacturers software innovators and service providers are differentiating through partnerships aftermarket services and flexible commercial models

Leading organizations in the radiotherapy ecosystem are pursuing differentiated strategies that blend technological innovation, service excellence, and strategic partnerships. Established equipment manufacturers continue to invest in integrated systems that combine hardware, advanced imaging, and software-driven planning to create stickier customer relationships and recurring revenue streams through service and software licensing. These incumbents are also expanding aftermarket offerings, such as predictive maintenance and remote diagnostics, to improve uptime and protect long-term installed base value.

At the same time, software vendors and digital health entrants are carving out influence by delivering automation, workflow orchestration, and outcome analytics that address clinician efficiency and quality assurance gaps. Startups focused on AI-driven contouring, adaptive planning, and dose optimization are engaging in strategic collaborations with device makers and academic centers to validate clinical benefit and accelerate regulatory acceptance. Partnerships with academic and clinical leaders provide an important bridge to real-world evidence generation and payer engagement.

Competitive dynamics also include consolidation among component suppliers and service providers as companies seek scale to support global service networks and localized manufacturing. Firms that combine deep clinical depth with flexible commercial models-such as leasing, pay-per-use, or outcome-linked contracts-are better positioned to address procurement constraints and demonstrate return on investment. Overall, the competitive landscape rewards firms that can deliver demonstrable clinical value, robust support ecosystems, and adaptable financing to meet the diverse needs of health systems around the world.

Practical and prioritized recommendations for executives to strengthen supply chain resilience accelerate clinical adoption enhance workforce capabilities and align commercial models with value delivery

Industry leaders should adopt a portfolio approach that balances near-term resilience with long-term clinical differentiation. Diversifying supply chains and increasing component localization where feasible will reduce exposure to tariff disruptions and customs-related delays, while strategic inventory and parts consignment programs can preserve clinical uptime. Procurement teams should evaluate a mix of acquisition, leasing, and outcome-linked contracting to optimize capital utilization and align incentives between vendors and health systems.

Investment in digital enablement and workforce competency will pay dividends. Vendors and providers should co-invest in training programs, remote service capabilities, and embedded decision-support tools that reduce variability and accelerate adoption of advanced workflows. Demonstrating clinical and economic value through rigorous real-world evidence generation will be essential to secure reimbursement and justify premium technologies. In parallel, companies must establish clear regulatory strategies that anticipate evolving standards for AI, software-as-a-medical-device, and particle therapy modalities.

Collaboration is critical: forging partnerships with academic centers, payers, and multidisciplinary oncology networks will facilitate clinical validation and broaden referral bases. Leaders should also pursue modular product architectures and interoperable software platforms to enable incremental upgrades and smoother integration into existing clinical ecosystems. By combining supply chain resilience, educational investment, evidence generation, and flexible commercial models, organizations can navigate near-term headwinds while positioning themselves for sustainable growth and clinical impact.

Transparent explanation of the mixed methods research framework expert interviews literature review regulatory mapping and supply chain analysis that supports the insights and recommendations

The analysis underpinning this executive summary rests on a rigorous mixed-methods research design that triangulates primary interviews, clinical literature, regulatory records, and supply chain intelligence. Primary research included structured discussions with radiation oncologists, medical physicists, hospital procurement leaders, and senior executives from vendors and service providers to capture first-hand perspectives on technology utility, adoption barriers, and operational constraints. Clinical practice trends were corroborated through a systematic review of peer-reviewed publications, clinical guidelines, and conference proceedings to ensure alignment with contemporary evidence and emerging consensus.

Secondary sources comprised regulatory filings, device technical documentation, and publicly available service contracts to map product capabilities, certification pathways, and contractual norms. Supply chain analysis leveraged import/export data, component sourcing trends, and manufacturing footprint mapping to assess vulnerability points and potential mitigation levers. Quality assurance protocols included cross-validation of interview findings, iterative expert review, and scenario testing to probe the implications of tariffs, technology adoption curves, and workforce trends. Wherever applicable, ethical considerations and data governance issues were reviewed to ensure recommendations respect patient safety and privacy standards.

This methodological approach emphasizes transparency, reproducibility, and relevance to executive decision-making, ensuring that insights reflect both the lived realities of clinical practice and the strategic levers available to industry stakeholders.

Concise conclusion emphasizing the imperative for resilient strategies innovation partnerships and evidence generation to deliver sustainable high quality radiotherapy services

The landscape of radiotherapy is at an inflection point where technological advancement, commercial strategy, and health system priorities converge to shape the next era of cancer care. Precision imaging, adaptive planning, and particle therapies expand clinical options while simultaneously raising the bar for training, service reliability, and financing. Tariff-driven supply chain changes and shifting procurement models underscore the need for resilient, flexible strategies that preserve clinical access while managing total cost implications.

Executives should focus on integrating advanced technologies in ways that deliver measurable clinical benefit, investing in workforce capability, and building service models that ensure uptime and long-term value. Collaborations between vendors, clinical leaders, and payers will be crucial to demonstrate outcomes and align incentives. Ultimately, organizations that combine operational resilience, evidence-generation capacity, and patient-centered implementation will lead in delivering high-quality, sustainable radiotherapy services in a rapidly evolving environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of AI-driven automated treatment planning systems to optimize delivery efficiency and accuracy
  • 5.2. Integration of MR-guided radiotherapy systems to enable real-time soft tissue visualization and adaptive dosing
  • 5.3. Expansion of proton therapy centers driving precision treatment options for pediatric and complex tumors
  • 5.4. Growing use of hypofractionated radiotherapy protocols to reduce patient visits and improve quality of life
  • 5.5. Emergence of FLASH radiotherapy accelerating ultra-high dose rates for enhanced normal tissue sparing
  • 5.6. Utilization of radiomics and genomics data for personalized adaptive radiotherapy treatment planning approaches
  • 5.7. Deployment of cloud-based oncology platforms facilitating remote collaboration and big data analytics in radiotherapy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Radiotherapy Market, by Component

  • 8.1. Hardware
    • 8.1.1. Brachytherapy Afterloaders
    • 8.1.2. Gamma Knife Systems
    • 8.1.3. Imaging & Guidance Systems
    • 8.1.4. Linear Accelerators (LINACs)
    • 8.1.5. Multileaf Collimators (MLCs)
    • 8.1.6. Proton Therapy Systems
  • 8.2. Service
    • 8.2.1. Maintenance & Calibration
    • 8.2.2. Training & Consulting
  • 8.3. Software
    • 8.3.1. Dose Calculation
    • 8.3.2. Patient Workflow Systems
    • 8.3.3. Treatment Planning

9. Radiotherapy Market, by Radiotherapy Type

  • 9.1. Brachytherapy
  • 9.2. External Beam Radiotherapy
    • 9.2.1. 3D Conformal Radiation Therapy
    • 9.2.2. Image-Guided Radiation Therapy
    • 9.2.3. Intensity-Modulated Radiation Therapy
    • 9.2.4. MR-guided Radiotherapy
    • 9.2.5. Proton Beam Therapy
    • 9.2.6. Stereotactic Body Radiotherapy
    • 9.2.7. Stereotactic Radiosurgery
    • 9.2.8. TomoTherapy
    • 9.2.9. Volumetric Modulated Arc Therapy
  • 9.3. Systemic Radiotherapy
    • 9.3.1. Radioimmunotherapy
    • 9.3.2. Radiopharmaceutical-based
    • 9.3.3. Targeted Alpha Therapy

10. Radiotherapy Market, by Technology

  • 10.1. Advanced Radiotherapy
    • 10.1.1. Image-guided Radiotherapy
    • 10.1.2. Particle Therapy
      • 10.1.2.1. Carbon-ion
      • 10.1.2.2. Neutron
      • 10.1.2.3. Proton
  • 10.2. Conventional Radiotherapy

11. Radiotherapy Market, by Application

  • 11.1. Brain Tumors
  • 11.2. Breast Cancer
  • 11.3. Cervical Cancer
  • 11.4. Colorectal Cancer
  • 11.5. Gastrointestinal Cancer
  • 11.6. Head & Neck Cancer
  • 11.7. Liver Cancer
  • 11.8. Lung Cancer
  • 11.9. Prostate Cancer
  • 11.10. Spine Cancer

12. Radiotherapy Market, by End User

  • 12.1. Advanced Radio Oncology Centers
  • 12.2. Hospitals
  • 12.3. Oncology Clinics

13. Radiotherapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Radiotherapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Radiotherapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Accuray Incorporated
    • 16.3.2. Agilent Technologies Inc.
    • 16.3.3. Cardinal Health, Inc.
    • 16.3.4. Charles River Laboratories International, Inc.
    • 16.3.5. Elekta AB
    • 16.3.6. GE HealthCare Technologies Inc.
    • 16.3.7. IBA Dosimetry GmbH
    • 16.3.8. IntraOp Medical, Inc.
    • 16.3.9. Koninklijke Philips N.V.
    • 16.3.10. Leo Cancer Care
    • 16.3.11. Mevion Medical Systems, Inc.
    • 16.3.12. Panacea Medical Technologies Pvt. Ltd.
    • 16.3.13. Revvity, Inc.
    • 16.3.14. Epsilon Elektronik by BOZLU HOLDING Corporation
    • 16.3.15. Siemens AG
    • 16.3.16. ZEISS Group
    • 16.3.17. Canon Medical Systems Corporation
    • 16.3.18. Hitachi, Ltd.
    • 16.3.19. ViewRay Technologies, Inc.
    • 16.3.20. BEBIG Medical GmbH
    • 16.3.21. Vision RT Ltd.
    • 16.3.22. Toshiba Corporation
    • 16.3.23. Mitsubishi Electric Corporation
    • 16.3.24. RefleXion Medical Inc.
    • 16.3.25. Sumitomo Heavy Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RADIOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RADIOTHERAPY MARKET SIZE, BY COMPONENT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RADIOTHERAPY MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOTHERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOTHERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RADIOTHERAPY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RADIOTHERAPY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RADIOTHERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL RADIOTHERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RADIOTHERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL RADIOTHERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RADIOTHERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS RADIOTHERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RADIOTHERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL RADIOTHERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. RADIOTHERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. RADIOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RADIOTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RADIOTHERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RADIOTHERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RADIOTHERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RADIOTHERAPY MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RADIOTHERAPY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RADIOTHERAPY MARKET SIZE, BY HARDWARE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RADIOTHERAPY MARKET SIZE, BY HARDWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RADIOTHERAPY MARKET SIZE, BY HARDWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RADIOTHERAPY MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RADIOTHERAPY MARKET SIZE, BY HARDWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RADIOTHERAPY MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RADIOTHERAPY MARKET SIZE, BY HARDWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRACHYTHERAPY AFTERLOADERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRACHYTHERAPY AFTERLOADERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRACHYTHERAPY AFTERLOADERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRACHYTHERAPY AFTERLOADERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRACHYTHERAPY AFTERLOADERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRACHYTHERAPY AFTERLOADERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RADIOTHERAPY MARKET SIZE, BY GAMMA KNIFE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RADIOTHERAPY MARKET SIZE, BY GAMMA KNIFE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RADIOTHERAPY MARKET SIZE, BY GAMMA KNIFE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RADIOTHERAPY MARKET SIZE, BY GAMMA KNIFE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RADIOTHERAPY MARKET SIZE, BY GAMMA KNIFE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RADIOTHERAPY MARKET SIZE, BY GAMMA KNIFE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGING & GUIDANCE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGING & GUIDANCE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGING & GUIDANCE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGING & GUIDANCE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGING & GUIDANCE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGING & GUIDANCE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RADIOTHERAPY MARKET SIZE, BY LINEAR ACCELERATORS (LINACS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RADIOTHERAPY MARKET SIZE, BY LINEAR ACCELERATORS (LINACS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RADIOTHERAPY MARKET SIZE, BY LINEAR ACCELERATORS (LINACS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RADIOTHERAPY MARKET SIZE, BY LINEAR ACCELERATORS (LINACS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RADIOTHERAPY MARKET SIZE, BY LINEAR ACCELERATORS (LINACS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RADIOTHERAPY MARKET SIZE, BY LINEAR ACCELERATORS (LINACS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RADIOTHERAPY MARKET SIZE, BY MULTILEAF COLLIMATORS (MLCS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RADIOTHERAPY MARKET SIZE, BY MULTILEAF COLLIMATORS (MLCS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RADIOTHERAPY MARKET SIZE, BY MULTILEAF COLLIMATORS (MLCS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RADIOTHERAPY MARKET SIZE, BY MULTILEAF COLLIMATORS (MLCS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RADIOTHERAPY MARKET SIZE, BY MULTILEAF COLLIMATORS (MLCS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RADIOTHERAPY MARKET SIZE, BY MULTILEAF COLLIMATORS (MLCS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON THERAPY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON THERAPY SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON THERAPY SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON THERAPY SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON THERAPY SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON THERAPY SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RADIOTHERAPY MARKET SIZE, BY SERVICE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RADIOTHERAPY MARKET SIZE, BY SERVICE, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RADIOTHERAPY MARKET SIZE, BY SERVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RADIOTHERAPY MARKET SIZE, BY SERVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RADIOTHERAPY MARKET SIZE, BY SERVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RADIOTHERAPY MARKET SIZE, BY SERVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RADIOTHERAPY MARKET SIZE, BY SERVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RADIOTHERAPY MARKET SIZE, BY SERVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RADIOTHERAPY MARKET SIZE, BY MAINTENANCE & CALIBRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RADIOTHERAPY MARKET SIZE, BY MAINTENANCE & CALIBRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RADIOTHERAPY MARKET SIZE, BY MAINTENANCE & CALIBRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RADIOTHERAPY MARKET SIZE, BY MAINTENANCE & CALIBRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RADIOTHERAPY MARKET SIZE, BY MAINTENANCE & CALIBRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RADIOTHERAPY MARKET SIZE, BY MAINTENANCE & CALIBRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RADIOTHERAPY MARKET SIZE, BY TRAINING & CONSULTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RADIOTHERAPY MARKET SIZE, BY TRAINING & CONSULTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RADIOTHERAPY MARKET SIZE, BY TRAINING & CONSULTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RADIOTHERAPY MARKET SIZE, BY TRAINING & CONSULTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RADIOTHERAPY MARKET SIZE, BY TRAINING & CONSULTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RADIOTHERAPY MARKET SIZE, BY TRAINING & CONSULTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RADIOTHERAPY MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RADIOTHERAPY MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RADIOTHERAPY MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RADIOTHERAPY MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RADIOTHERAPY MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RADIOTHERAPY MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RADIOTHERAPY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RADIOTHERAPY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RADIOTHERAPY MARKET SIZE, BY DOSE CALCULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RADIOTHERAPY MARKET SIZE, BY DOSE CALCULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RADIOTHERAPY MARKET SIZE, BY DOSE CALCULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RADIOTHERAPY MARKET SIZE, BY DOSE CALCULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RADIOTHERAPY MARKET SIZE, BY DOSE CALCULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RADIOTHERAPY MARKET SIZE, BY DOSE CALCULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RADIOTHERAPY MARKET SIZE, BY PATIENT WORKFLOW SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RADIOTHERAPY MARKET SIZE, BY PATIENT WORKFLOW SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RADIOTHERAPY MARKET SIZE, BY PATIENT WORKFLOW SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RADIOTHERAPY MARKET SIZE, BY PATIENT WORKFLOW SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RADIOTHERAPY MARKET SIZE, BY PATIENT WORKFLOW SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RADIOTHERAPY MARKET SIZE, BY PATIENT WORKFLOW SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RADIOTHERAPY MARKET SIZE, BY TREATMENT PLANNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RADIOTHERAPY MARKET SIZE, BY TREATMENT PLANNING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RADIOTHERAPY MARKET SIZE, BY TREATMENT PLANNING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RADIOTHERAPY MARKET SIZE, BY TREATMENT PLANNING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RADIOTHERAPY MARKET SIZE, BY TREATMENT PLANNING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RADIOTHERAPY MARKET SIZE, BY TREATMENT PLANNING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOTHERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOTHERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RADIOTHERAPY MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RADIOTHERAPY MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RADIOTHERAPY MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RADIOTHERAPY MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RADIOTHERAPY MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RADIOTHERAPY MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RADIOTHERAPY MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RADIOTHERAPY MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RADIOTHERAPY MARKET SIZE, BY 3D CONFORMAL RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RADIOTHERAPY MARKET SIZE, BY 3D CONFORMAL RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RADIOTHERAPY MARKET SIZE, BY 3D CONFORMAL RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RADIOTHERAPY MARKET SIZE, BY 3D CONFORMAL RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL RADIOTHERAPY MARKET SIZE, BY 3D CONFORMAL RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL RADIOTHERAPY MARKET SIZE, BY 3D CONFORMAL RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGE-GUIDED RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGE-GUIDED RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGE-GUIDED RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGE-GUIDED RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGE-GUIDED RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGE-GUIDED RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL RADIOTHERAPY MARKET SIZE, BY INTENSITY-MODULATED RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL RADIOTHERAPY MARKET SIZE, BY INTENSITY-MODULATED RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL RADIOTHERAPY MARKET SIZE, BY INTENSITY-MODULATED RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL RADIOTHERAPY MARKET SIZE, BY INTENSITY-MODULATED RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL RADIOTHERAPY MARKET SIZE, BY INTENSITY-MODULATED RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL RADIOTHERAPY MARKET SIZE, BY INTENSITY-MODULATED RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL RADIOTHERAPY MARKET SIZE, BY MR-GUIDED RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL RADIOTHERAPY MARKET SIZE, BY MR-GUIDED RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL RADIOTHERAPY MARKET SIZE, BY MR-GUIDED RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL RADIOTHERAPY MARKET SIZE, BY MR-GUIDED RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL RADIOTHERAPY MARKET SIZE, BY MR-GUIDED RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL RADIOTHERAPY MARKET SIZE, BY MR-GUIDED RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON BEAM THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON BEAM THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON BEAM THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON BEAM THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON BEAM THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON BEAM THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL RADIOTHERAPY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL RADIOTHERAPY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL RADIOTHERAPY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL RADIOTHERAPY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL RADIOTHERAPY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL RADIOTHERAPY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL RADIOTHERAPY MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL RADIOTHERAPY MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL RADIOTHERAPY MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL RADIOTHERAPY MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL RADIOTHERAPY MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL RADIOTHERAPY MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL RADIOTHERAPY MARKET SIZE, BY TOMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL RADIOTHERAPY MARKET SIZE, BY TOMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL RADIOTHERAPY MARKET SIZE, BY TOMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL RADIOTHERAPY MARKET SIZE, BY TOMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL RADIOTHERAPY MARKET SIZE, BY TOMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL RADIOTHERAPY MARKET SIZE, BY TOMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL RADIOTHERAPY MARKET SIZE, BY VOLUMETRIC MODULATED ARC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL RADIOTHERAPY MARKET SIZE, BY VOLUMETRIC MODULATED ARC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL RADIOTHERAPY MARKET SIZE, BY VOLUMETRIC MODULATED ARC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL RADIOTHERAPY MARKET SIZE, BY VOLUMETRIC MODULATED ARC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL RADIOTHERAPY MARKET SIZE, BY VOLUMETRIC MODULATED ARC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL RADIOTHERAPY MARKET SIZE, BY VOLUMETRIC MODULATED ARC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL RADIOTHERAPY MARKET SIZE, BY SYSTEMIC RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL RADIOTHERAPY MARKET SIZE, BY SYSTEMIC RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL RADIOTHERAPY MARKET SIZE, BY SYSTEMIC RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL RADIOTHERAPY MARKET SIZE, BY SYSTEMIC RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL RADIOTHERAPY MARKET SIZE, BY SYSTEMIC RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL RADIOTHERAPY MARKET SIZE, BY SYSTEMIC RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL RADIOTHERAPY MARKET SIZE, BY SYSTEMIC RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL RADIOTHERAPY MARKET SIZE, BY SYSTEMIC RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOPHARMACEUTICAL-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOPHARMACEUTICAL-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOPHARMACEUTICAL-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOPHARMACEUTICAL-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOPHARMACEUTICAL-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL RADIOTHERAPY MARKET SIZE, BY RADIOPHARMACEUTICAL-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL RADIOTHERAPY MARKET SIZE, BY TARGETED ALPHA THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL RADIOTHERAPY MARKET SIZE, BY TARGETED ALPHA THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL RADIOTHERAPY MARKET SIZE, BY TARGETED ALPHA THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL RADIOTHERAPY MARKET SIZE, BY TARGETED ALPHA THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL RADIOTHERAPY MARKET SIZE, BY TARGETED ALPHA THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL RADIOTHERAPY MARKET SIZE, BY TARGETED ALPHA THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL RADIOTHERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL RADIOTHERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL RADIOTHERAPY MARKET SIZE, BY ADVANCED RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL RADIOTHERAPY MARKET SIZE, BY ADVANCED RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL RADIOTHERAPY MARKET SIZE, BY ADVANCED RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL RADIOTHERAPY MARKET SIZE, BY ADVANCED RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL RADIOTHERAPY MARKET SIZE, BY ADVANCED RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL RADIOTHERAPY MARKET SIZE, BY ADVANCED RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL RADIOTHERAPY MARKET SIZE, BY ADVANCED RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL RADIOTHERAPY MARKET SIZE, BY ADVANCED RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGE-GUIDED RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGE-GUIDED RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGE-GUIDED RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGE-GUIDED RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGE-GUIDED RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL RADIOTHERAPY MARKET SIZE, BY IMAGE-GUIDED RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL RADIOTHERAPY MARKET SIZE, BY PARTICLE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL RADIOTHERAPY MARKET SIZE, BY PARTICLE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL RADIOTHERAPY MARKET SIZE, BY PARTICLE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL RADIOTHERAPY MARKET SIZE, BY PARTICLE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL RADIOTHERAPY MARKET SIZE, BY PARTICLE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL RADIOTHERAPY MARKET SIZE, BY PARTICLE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL RADIOTHERAPY MARKET SIZE, BY PARTICLE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL RADIOTHERAPY MARKET SIZE, BY PARTICLE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL RADIOTHERAPY MARKET SIZE, BY CARBON-ION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL RADIOTHERAPY MARKET SIZE, BY CARBON-ION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL RADIOTHERAPY MARKET SIZE, BY CARBON-ION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL RADIOTHERAPY MARKET SIZE, BY CARBON-ION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL RADIOTHERAPY MARKET SIZE, BY CARBON-ION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL RADIOTHERAPY MARKET SIZE, BY CARBON-ION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL RADIOTHERAPY MARKET SIZE, BY NEUTRON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL RADIOTHERAPY MARKET SIZE, BY NEUTRON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL RADIOTHERAPY MARKET SIZE, BY NEUTRON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL RADIOTHERAPY MARKET SIZE, BY NEUTRON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL RADIOTHERAPY MARKET SIZE, BY NEUTRON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL RADIOTHERAPY MARKET SIZE, BY NEUTRON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROTON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL RADIOTHERAPY MARKET SIZE, BY CONVENTIONAL RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL RADIOTHERAPY MARKET SIZE, BY CONVENTIONAL RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL RADIOTHERAPY MARKET SIZE, BY CONVENTIONAL RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL RADIOTHERAPY MARKET SIZE, BY CONVENTIONAL RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL RADIOTHERAPY MARKET SIZE, BY CONVENTIONAL RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL RADIOTHERAPY MARKET SIZE, BY CONVENTIONAL RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL RADIOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL RADIOTHERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRAIN TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRAIN TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRAIN TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRAIN TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRAIN TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL RADIOTHERAPY MARKET SIZE, BY BRAIN TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL RADIOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL RADIOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL RADIOTHERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL RADIOTHERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL RADIOTHERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL RADIOTHERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL RADIOTHERAPY MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL RADIOTHERAPY MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL RADIOTHERAPY MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL RADIOTHERAPY MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL RADIOTHERAPY MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL RADIOTHERAPY MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL RADIOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL RADIOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL RADIOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL RADIOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL RADIOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL RADIOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL RADIOTHERAPY MARKET SIZE, BY GASTROINTESTINAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL RADIOTHERAPY MARKET SIZE, BY GASTROINTESTINAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL RADIOTHERAPY MARKET SIZE, BY GASTROINTESTINAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL RADIOTHERAPY MARKET SIZE, BY GASTROINTESTINAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL RADIOTHERAPY MARKET SIZE, BY GASTROINTESTINAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL RADIOTHERAPY MARKET SIZE, BY GASTROINTESTINAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL RADIOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL RADIOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL RADIOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL RADIOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL RADIOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL RADIOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL RADIOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL RADIOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL RADIOTHERAPY MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL RADIOTHERAPY MARKET SIZE, BY LIVER CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL RADIOTHERAPY MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL RADIOTHERAPY MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL RADIOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL RADIOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL RADIOTHERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL RADIOTHERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL RADIOTHERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL RADIOTHERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL RADIOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL RADIOTHERAPY MARKET SIZE, BY SPINE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL RADIOTHERAPY MARKET SIZE, BY SPINE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL RADIOTHERAPY MARKET SIZE, BY SPINE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL RADIOTHERAPY MARKET SIZE, BY SPINE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL RADIOTHERAPY MARKET SIZE, BY SPINE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL RADIOTHERAPY MARKET SIZE, BY SPINE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL RADIOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL RADIOTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL RADIOTHERAPY MARKET SIZE, BY ADVANCED RADIO ONCOLOGY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL RADIOTHERAPY MARKET SIZE, BY ADVANCED RADIO ONCOLOGY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL RADIOTHERAPY MARKET SIZE, BY ADVANCED RADIO ONCOLOGY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL RADIOTHERAPY MARKET SIZE, BY ADVANCED RADIO ONCOLOGY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL RADIOTHERAPY MARKET SIZE, BY ADVANCED RADIO ONCOLOGY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL RADIOTHERAPY MARKET SIZE, BY ADVANCED RADIO ONCOLOGY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL RADIOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL RADIOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL RADIOTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL RADIOTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL RADIOTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL RADIOTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL RADIOTHERAPY MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL RADIOTHERAPY MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL RADIOTHERAPY MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL RADIOTHERAPY MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 321. GLOBAL RADIOTHERAPY MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. GLOBAL RADIOTHERAPY MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL RADIOTHERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL RADIOTHERAPY MARKET SIZE, BY REGION, 2025-2032 (US